<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03896646</url>
  </required_header>
  <id_info>
    <org_study_id>2018-1008</org_study_id>
    <secondary_id>NCI-2019-01586</secondary_id>
    <secondary_id>2018-1008</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03896646</nct_id>
  </id_info>
  <brief_title>Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)</brief_title>
  <official_title>Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to improve hepatocellular carcinoma (HCC) tumor responses in patients
      undergoing Y90 radioembolization by using personalized dosimetry as part of treatment
      planning. Using standard calculations for Y90 doses may not be specific enough for individual
      patients given that there can be differences in how tumor cells and liver cells respond to
      radiation. Personalized dose plans may help improve treatment and outcomes in liver cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To achieve tumor objective response rates of 75% using voxel based dosimetry when the mean
      dose (Dmean) to tumor is targeted to be greater than 200 Gray (Gy).

      SECONDARY OBJECTIVES:

      I. Correlate changes in liver function and Common Terminology Criteria for Adverse Events
      (CTCAE) incidence to the mean absorbed dose to normal liver.

      II. Prospectively validate the accuracy of our published tumor dose response prediction based
      on the yttrium Y 90 glass microspheres (yttrium-90 [Y90]) tumor dose volume histograms
      (DVHs).

      III. Correlate predicted tumor doses macroaggregated albumin (MAA) scan with actual doses
      delivered (Y90 scan).

      IV. Develop a tumor dose response model prediction based on the MAA dose maps. V. Develop a
      model correlating normal liver radiation dose to liver function using single-photon emission
      computed tomography/computed tomography hepatobiliary iminodiacetic acid (SPECT/CT HIDA)
      imaging.

      VI. Develop a model correlating the relative tumor to normal liver enhancement on CT imaging
      and Cone beam CT imaging to the uptake on SPECT CT Tc99m MAA imaging (gold standard).

      VII. Compare tumor and normal liver doses estimations from SPECT CT Bremsstrahlung imaging to
      positron emission tomography (PET) CT imaging.

      OUTLINE:

      Patients undergo yttrium-90 microsphere radioembolization with yttrium Y 90 glass
      microspheres using personalized dose measurements. Patients also undergo SPECT/CT HIDA scan
      before radioembolization and 2-4 months after radioembolization.

      After completion of study treatment, patients are followed up at 3 and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor objective response rate (ORR)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Assessed with modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. The ORR of treated tumors will be determined. Will perform a cluster bootstrap in which patients (not tumors) are sampled with replacement. Will construct a 95% confidence interval using the 2.5% and 97.5% quantiles of the bootstrap sampling distribution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in liver function</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will analyze the correlation in changes in liver function to the mean absorbed dose to normal liver. The hepatobiliary iminodiacetic acid (HIDA) scan will be used to estimate the body-surface area corrected mebrofenin clearance rate in %-activity/sec/m^2 using published methodology. The change in liver function after radioembolization will be calculated and correlated to the radiation dose distribution to the normal liver. Will use Wilcoxon and two-sample t-tests to measure significance of association.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Common Terminology Criteria for Adverse Events (CTCAE) incidence</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will analyze the correlation in changes in CTCAE incidence to the mean absorbed dose to normal liver. Will create waterfall charts of CTCAE and mean absorbed normal liver in liver. Will use Wilcoxon and two-sample t-tests to measure significance of association and scatterplots and regression (linear or non-linear) to predict actual doses delivered from predicted tumor dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of published tumor dose response prediction based on the yttrium-90 (Y90) tumor dose volume histograms</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Lin's concordance correlation, t-test, and Bland-Altman analysis will be performed on pair-wise estimate of tumor doses. Develop tumor dose response curves using logistic regression and assess significance of parameters. Furthermore, we will compute the half-maximal dose (D50%), positive predictive value, negative predictive value and its 95% confidence interval from this prospective study. These values will be compared to those from the retrospective study for equivalence using the z-test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of tumor doses macroaggregated albumin (MAA) scan with actual doses delivered (Y90 scan)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Lin's concordance correlation, t-test, and Bland-Altman analysis will be performed on pair-wise estimate of tumor doses. Will use scatterplots and regression (linear or non-linear) to predict actual doses delivered from predicted tumor dose. A correlation analysis of the predicted tumor doses from the MAA images with the actual tumor doses delivered from Y90 images will be performed. The linear-correlation coefficient will be computed. A Bland-Altman analysis will be performed to compute the bias and the 95% limits of agreement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of tumor dose response model prediction based on MAA dose maps</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Mean tumor doses based the planning 99mTc-MAA images will be computed using voxel dosimetry. A univariate logistic regression model will used to determine tumor dose metrics (D50%) that correlated with mRECIST-based tumor response at 3 and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of a model correlating normal liver radiation dose to liver function using single-photon emission computed tomography computed tomography hepatobiliary iminodiacetic acid (SPECT CT HIDA) imaging</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>A regression analysis of the change in liver function from the pre- and post-procedural HIDA SPECT/CT scans (changes in %/min) as a function of the normal liver absorbed dose will be performed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Stage III Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IIIA Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IIIB Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IV Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IVA Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IVB Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Unresectable Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (personalized radioembolization, SPECT/CT HIDA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo yttrium-90 microsphere radioembolization with yttrium Y 90 glass microspheres using personalized dose measurements. Patients also undergo SPECT/CT HIDA scan before radioembolization and 2-4 months after radioembolization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo SPECT/CT HIDA scan</description>
    <arm_group_label>Treatment (personalized radioembolization, SPECT/CT HIDA)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hepatobiliary Iminodiacetic Acid Scan</intervention_name>
    <description>Undergo SPECT/CT HIDA scan</description>
    <arm_group_label>Treatment (personalized radioembolization, SPECT/CT HIDA)</arm_group_label>
    <other_name>HIDA Scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single Photon Emission Computed Tomography</intervention_name>
    <description>Undergo SPECT/CT HIDA scan</description>
    <arm_group_label>Treatment (personalized radioembolization, SPECT/CT HIDA)</arm_group_label>
    <other_name>Medical Imaging, Single Photon Emission Computed Tomography</other_name>
    <other_name>Single Photon Emission Tomography</other_name>
    <other_name>single-photon emission computed tomography</other_name>
    <other_name>SPECT</other_name>
    <other_name>SPECT imaging</other_name>
    <other_name>SPECT SCAN</other_name>
    <other_name>SPET</other_name>
    <other_name>tomography, emission computed, single photon</other_name>
    <other_name>Tomography, Emission-Computed, Single-Photon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Yttrium Y 90 Glass Microspheres</intervention_name>
    <description>Undergo radioembolization with yttrium Y 90 glass microspheres</description>
    <arm_group_label>Treatment (personalized radioembolization, SPECT/CT HIDA)</arm_group_label>
    <other_name>TheraSphere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Yttrium-90 Microsphere Radioembolization</intervention_name>
    <description>Undergo yttrium-90 microsphere radioembolization</description>
    <arm_group_label>Treatment (personalized radioembolization, SPECT/CT HIDA)</arm_group_label>
    <other_name>Yttrium Y 90 Microsphere Therapy</other_name>
    <other_name>Yttrium-90 Radioembolization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients over 18 years of age, of any race or sex, who have unresectable
             hepatocellular carcinoma of the liver, and who are able or have a fully able legal
             guardian to give informed consent, will be eligible. Patients must have an ECOG
             Performance Status score of &lt;/=2, with a life expectancy of &gt;/=3 months, and must be
             non-pregnant with an acceptable contraception in premenopausal women. Patients must be
             &gt;4 weeks since prior radiation or prior surgery and at least one month post
             chemotherapy.

          2. At least one lesion &gt;/= 3.0 cm in shortest dimension

          3. AST or ALT &lt;5 times ULN

          4. Bilirubin &lt;/= 2.0 mg/dL (unless segmental infusion is used)

          5. Negative pregnancy test in premenopausal women

        Exclusion Criteria:

          1. Contraindications to angiography and selective visceral catheterization

          2. Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) to the
             lungs with a single injection, or greater than 50 Gy for multiple injections

          3. Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after
             application of established angiographic techniques to stop or mitigate such flow (eg,
             placing catheter distal to gastric vessels)

          4. Significant extrahepatic disease representing an imminent life-threatening outcome

          5. Severe liver dysfunction or pulmonary insufficiency

          6. Active uncontrolled infection

          7. Significant underlying medical or psychiatric illness

          8. Pregnant

          9. Pre-existing diarrhea/illness, co-morbid disease or condition that would preclude safe
             delivery of TheraSphereÂ® treatment and place the patient at undue risk

         10. Infiltrative tumors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armeen Mahvash</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armeen Mahvash</last_name>
    <phone>713-563-7340</phone>
    <email>armeen.mahvash@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armeen Mahvash</last_name>
      <phone>713-563-7340</phone>
    </contact>
    <investigator>
      <last_name>Armeen Mahvash</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>March 28, 2020</last_update_submitted>
  <last_update_submitted_qc>March 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iminodiacetic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

